Stem cells are self-renewing elements that can generate the many cell types in the body. They are found in adult and fetal tissues, but the stem cells with the widest developmental potential are derived from an early stage of the mammalian embryo and are named embryonic stem (ES) cells. The isolation of human ES cells and the related embryonic germ (EG) cells has stimulated discussion of the appropriate balance between the clinical benefit and ethical concerns associated with this developing technology (1, 2) . ES cells were first obtained in the mouse system where their ability to generate different cell types in vitro has been studied by several groups. This work has defined conditions that promote differentiation of ES cells into cell types found in the blood, heart, muscle, blood vessels, and brain (3) (4) (5) (6) . Here we show that the ES cells can be efficiently induced to differentiate into insulin-producing and other cell types typical of endocrine pancreas and that these cells can self-assemble to form functional pancreatic islet-like structures. These results suggest that ES cells will provide a powerful tool to study pancreatic development, function, and disease.
The pancreas is composed of exocrine and endocrine compartments. The endocrine compartment consists of islets of Langerhans, clusters of four cell types that synthesize peptide hormones: insulin (␤ cells), glucagon (␣ cells), somatostatin (␦ cells), and pancreatic polypeptide (PP cells). The endocrine cells in the islets are organized in a stereotypical topological order and are in close contact with neurons. During embryogenesis, the pancreas develops from a single cell layer of definitive endoderm that contacts the notochord (7) . Although the adult pancreas and central nervous system (CNS) have distinct origins and functions, similar mechanisms control the development of both organs (8) (9) (10) . On the basis of these similarities, we hypothesized that strategies that induce production of neural cells from ES cells could be adapted for endocrine pancreatic cells (5, 11) . One of the early steps during neural differentiation of ES cells generates cell populations expressing nestin, an intermediate filament protein normally found in neural precursor cells (12) . Because nestin has also been recently identified in a subset of immature hormone-negative pancreatic cells (13) that, upon differentiation in vitro, give rise to insulin-and glucagon-expressing cells, we examined the expression of endocrine pancreatic genes by the progeny of nestinpositive cell populations derived from ES cells.
Our experimental strategy (14) (Fig. 1A ) begins with the production of a highly enriched population of nestin-positive cells from embryoid bodies (EBs) (stage 2). A critical step in this strategy is to plate the EBs into a serum-free medium (ITSFn) in which many other cell types die, thus increasing the proportion of nestin-positive cells (11) (stage 3). These cells were then expanded in the presence of a mitogen, basic fibroblast growth factor (bFGF), in N2 serum-free medium (11) (stage 4), followed by mitogen withdrawal to promote cessation of cell division and differentiation (stage 5). We found that including in the culture media a B27 supplement (15) (stages 4 and 5) and nicotinamide (16) (stage 5) improved the yield of pancreatic endocrine cells. The outcome of this method is the production of many aggregates of cells expressing insulin.
ES cells at stage 1 express a marker of definitive (embryonic) and visceral (extra-embryonic) endoderm GATA-4 and a marker of definitive endoderm HNF3␤. The ES cells at stage 5 also express GATA-4 and HNF3␤ as well as markers of pancreatic ␤ cell fate, including the murine insulin I, insulin II, islet amyloid polypeptide (IAPP), and the glucose transporter-2 (GLUT 2) (17) (Fig. 1B) . Glucagon, a marker for the pancreatic ␣ cell, was also induced in differentiated cells. The pancreatic transcription factor PDX-1, which is necessary for pancreatic development (18, 19) , was expressed in stage 1 cells. As judged by expression of markers of undifferentiated ES cells alkaline phosphatase and OCT-4 ( Fig. 2, A and B) (20) , the stage 1 cultures are composed predominantly of undifferentiated ES cells. We found that when stage 1 cultures are grown in the absence of feeder cells, they readily express PDX-1. This result indicates that initiation of pancreatic endocrine differentiation takes place early in the development of these ES cell cultures. In fact, expression of PDX-1 has been detected during initial stages of ES cell culture by other investigators (21, 22) . Expression of HNF3␤, implicated in control of PDX-1 gene expression, as well as visceral endoderm marker GATA-4 have been previously demonstrated to be present during early stages of differentiation of ES cells (22) . As Fig. 1B shows, PDX-1 expression is down-regulated during differentiation of ES cells. This down-regulation is not surprising, because it is known that PDX-1 mRNA is difficult to detect in the islets of adult rodents (23) . Overall, the results of reverse transcriptasepolymerase chain reaction (RT-PCR) analysis suggest that these conditions support the differentiation of pancreatic cells from endodermal precursors.
Immunocytochemistry (24) was used to identify progenitors, neurons, and insulin-positive cells in the ES cell cultures. Immunoreactivity to nestin was used to detect the differentiating progenitor cells. The intensity of nestin expression increased toward the end of stage 3 (Fig. 1C) , and many nestin-positive cells were also present during stage 4. The activation of nestin gene expression coincided with a drastic down-regulation of OCT-4 in stage 3 cells (Fig.  2B ). This result shows that efficient conversion of undifferentiated ES cells into nestin-positive progenitors occurs between stages 1 and 3. No insulin-positive cells were detected at stages 1 and 2, but a few cells appeared by the end of stage 3 (Fig. 1C) . At the end of stage 4, insulinand TUJ1-positive (neuron-specific ␤-III tubu-lin) (25) cells were present (Fig. 1C) . Insulin staining continued to increase after mitogen withdrawal, resulting in many strongly insulinpositive cells by the end of stage 5. The number and maturation of neurons also increased during this time, and by the end of stage 5 the majority of insulin-positive cells were localized in tight clusters in close association with neurons (Fig. 1C) . We reproducibly observed the same developmental expression pattern in numerous (more than 15) independent experiments and with two different ES cell lines [E14.1 (26) and B5 (27)].
To estimate the efficiency of generation of insulin-positive cells, we determined the number of insulin-positive cells as a percentage of total cells in the population. Because it is difficult to accurately count the cells in three-dimensional clusters ( Fig. 1C and Fig. 3 , A through C), we measured the number of insulin-positive cells after dissociation of the cell clusters (28, 29), 31.5 Ϯ 6.6% of which expressed insulin. This number may be somewhat exaggerated because neurons may be preferentially lost during cell dissociation procedure. These results show that this ES cell-based system generates large quantities of insulin-positive cells.
Confocal microscopy was used to analyze the morphology of the cell aggregates. A series of consecutive sections through a cluster shows that insulin-positive cells are located in the interior and are surrounded by neurons [height of the cluster shown (Fig. 3A) is 50 m and each section is 15 m thick]. Confocal images failed to detect any TUJ1-insulin double-labeled cells at any developmental stage. To characterize the differentiation further, we performed double immunostaining for insulin and three other pancreatic endocrine hormones: glucagon, somatostatin, and pancreatic polypeptide, which are normally produced by islet cells distinct from insulin-producing cells. We found that all three hormones are generated in the clusters. The majority of glucagon-and somatostatin-positive cells surround the insulin-positive cells (Fig. 3 , B and C). We failed to detect expression of the exocrine pancreatic markers amylase and carboxypeptidaseA by RT-PCR or of amylase by immunocytochemistry. The relative distribution of neurons and different types of endocrine cells in the clusters indicates that this system has the ability to generate multicellular structures topographically similar to in vivo pancreatic islets.
The efficient production of islet-like cells and neurons in this system might result from differentiation from two independent progenitors, or from a common progenitor. Clonal analysis was used to distinguish between these two possibilities (30). Because ES cells survive poorly when plated at clonal density, we cocultured green fluorescent protein (GFP)-tagged B5 ES cells with the wild-type E14.1 ES cells at stages 4 and 5. This allowed us to obtain individual clones of GFP-labeled cells arising among unlabeled wild-type cells (Fig.   4) . Interestingly, in the cytoplasm of GFPpositive cells, the GFP and insulin staining was never co-localized and GFP always surrounded insulin staining (Fig. 4A, inset) view of distinct embryonic origins of pancreatic and neural cells, this result may appear surprising. However, the common mechanisms of control and shared nestin expression point to a close relation between pancreatic and neural progenitors. Recent results with stem and progenitor cells of different cell types suggest that, in the future, we may need to re-evaluate and question some of our traditional views on cell lineage relations during differentiation (31). This ES cell-based system provides a useful model to further characterize the ontogeny of pancreatic progenitors.
To determine whether insulin-positive cells divide, the proliferating cells were labeled with bromodeoxyuridine (BrdU) at different time points during the culture and then were fixed and immunostained with antibodies to insulin and BrdU (32). The peak of cell proliferation coincides with the end of stage 4, but we did not detect BrdU-insulin double-labeled cells at any stage. These results suggest that in this ES cell system, like in vitro cultures of normal pancreatic precursors (33) , initiation of insulin expression coincides with inhibition of precursor cell proliferation. To determine when insulin expression is initiated, we used a pulse-chase
A series of experiments were conducted to measure glucose-dependent insulin release (34) . At the end of stage 5, the cells release insulin in response to glucose in a dosedependent manner with fast kinetics characteristic of primary pancreatic islets in vitro (Fig. 5A) (35) . Comparison of total cellular insulin content and insulin release at the end of stages 4 and 5 (Table 1) shows that insulin-secreting islet clusters undergo progressive maturation during stage 5. The total insulin content of the cells increased fivefold, and glucose-stimulated insulin release increased more that 40-fold between stages 4 and 5. Assuming that 15% of the cells are insulin-positive (the 15% figure was used to account for preferential death of neurons during cell dissociation), the 145 ng of insulin per milligram of protein translates into 1 g of insulin per milligram of protein in the insulin-positive subpopulation. Because the into the cell (Fig. 5B) . Additionally, intracellular Ca 2ϩ can be elevated by release of Ca 2ϩ from intracellular stores through other mechanisms. Elevation of free intracellular Ca 2ϩ is coupled to multiple phosphorylation events modulated by protein kinase C (PKC) and protein kinase A (PKA) cascades, which ultimately lead to release of insulin from the cell (36) . The results of the effect of the agonists and antagonists on insulin secretion are shown in lated insulin secretion in the presence of low concentration (5 mM) of glucose. Conversely, the antagonists, diazoxide, an activator of ATPdependent K ϩ channel (37) , and nifedipine, a blocker of L-type Ca 2ϩ channel (one of the Ca 2ϩ channels present in ␤ cells) (40) , inhibited insulin secretion in the presence of high glucose concentrations (20 mM). These results indicate that normal pancreatic machinery is used for glucose-mediated insulin release.
We began testing the potential of ES cellderived islet-like cell clusters to survive and function in vivo (41) . For these experiments, stage 5 cell clusters were grafted subcutaneously in the shoulder of streptozotocin-diabetic mice. The blood glucose levels and body weight were monitored at regular intervals. The grafts were harvested and examined after 7 days, 12 days, 4 weeks, and 6 weeks after implantation. The results of analysis of a representative 12-day graft demonstrate that implanted cells vascularize (Fig. 6A) and remain immunoreactive to insulin (Fig. 6B) . Moreover, insulin-positive cells form aggregates morphologically similar to normal pancreatic islets (Fig. 6C) . We observed analogous cell clustering and insulin immunorectivity in grafts harvested at other times. Although in these experiments we did not observe a sustained correction of hyperglycemia, the grafted animals were able to maintain their body weight and survived for longer periods of time than hyperglycemic sham-grafted controls, suggesting an overall beneficial effect of the grafted cells on the health of the animals. The lack of the diminution of hyperglycemia may not be surprising because the amount of insulin produced by these cells is considerably below that of the native pancreatic islets. Also, a subcutaneous cell implantation might not be ideal for glucose sensing. Nevertheless, these preliminary experiments clearly show the ability of the isletlike clusters to survive and express insulin in vivo.
It has been previously demonstrated that ES cells can coordinately differentiate into multiple cell types in vitro (6, 11) . We now report that in addition to producing multiple types of pancreatic endocrine cells, this ES cell-based system generates populations that self-assemble into structures resembling pancreatic islets both topologically and functionally. Interestingly, this self-assembling capacity parallels that of the normally dispersed pancreatic endocrine cells that were shown to spontaneously re-associate in vitro into aggregates with three-dimensional architecture typical of native islets (42) . The results further emphasize how the directed differentiation of ES cells may become a powerful tool to analyze mechanisms controlling the architecture of mammalian organs. It is important to recognize that although more work will be needed to increase insulin production by the cells and to establish various aspects of similarity of these clusters to normal islets, this is the first demonstration of the production of islet-like structures from ES cells. This advance provides an accessible model system to study endocrine progenitor cells, difficult to obtain by existing methods, at multiple stages of development. Another pancreatic ES cell-based system recently described (43) uses a gene trap strategy to isolate insulin-secreting cells from ES cells but does not identify the pancreatic progenitor cells that assemble into multicellular structures reported here.
In the clinical context, this ES cell-based system may allow simultaneous generation and assembly of insulin-secreting and other islet cell types known to play important role in regulation of insulin secretion into functional structural units. These units might provide material to optimize insulin production and analyze the fine control of glucose homeostasis. ES cells are ideal for these studies because genetic tools can be used to define the molecular basis of islet development and function. Potential for cell-based therapies is clearly an attractive goal for applications involving human and nonhuman ES and EG cells (1, 2, 11, 44) . Adult tissue may also be a useful source of functional pancreatic cells (45, 46) . The differentiation system described here may provide a source of functional pancreatic islets for treatment of diabetes. To our knowledge, this is the first report showing that the several cell types of endocrine pancreas can be generated from ES cells in vitro. Although pancreatic islets obtained from cadavers can function in the liver after grafting (47) , issues of tissue rejection and availability remain to be resolved. It is clear that engineering of ES cells to produce an abundant source of immunocompatible tissue for transplantation holds a growing promise for surmounting this and other problems associated with diabetes. The seeding efficiency and the growth of the plated B5 cells were monitored by immunocytochemical staining for GFP. Two hours after seeding, GFP-positive cells were present in 65 Ϯ 5% of the wells. Counterstaining with a nuclear dye (DAPI) confirmed presence of only one cell per well. After 6 days of differentiation, single GFP-labeled clones derived from a single B5 cell were present in 14.8 Ϯ 1.7% of the wells. Cells were cultured through stages 4 and 5, as shown in Fig. 1A . On day 6 of stage 5, cells were fixed with 4% paraformaldehyde and subjected to triple immunocytochemistry and laser confocal microscopy analysis. For immunocytochemistry, after blocking with a solution of 90% PBS, 10% normal goat serum, and 0.3% Triton-X100, cells were stained with antibodies against insulin [mouse immunoglobulin G1 (IgG1)], GFP (mouse IgG2a), and TUJ1 (rabbit). Cy5, FITC, and Cy3-conjugated goat antibodies to IgG1 mouse, IgG2a mouse and IgG rabbit, respectively, were used as secondary antibodies. 31. S. H. Orkin, Nature Med. 6, 1212 (2000). 32. The cells were labeled with BrdU (Boehringer Mannheim, Indianapolis, IN) at final concentration 10 m for 24 hours. After the labeling, depending on the specific experiment, the cells were either fixed immediately in 4% paraformaldehyde/0.15% picric acid, treated with 95% ethanol/5% glacial acidic acid for 15 min at room temperature, and subjected to immunocytochemistry,
